{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:50:26Z","timestamp":1766087426778,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2019.00810","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T03:35:34Z","timestamp":1563852934000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Method Validation for Simultaneous Quantification of Olmesartan and Hydrochlorothiazide in Human Plasma Using LC-MS\/MS and Its Application Through Bioequivalence Study in Healthy Volunteers"],"prefix":"10.3389","volume":"10","author":[{"given":"Arvind","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surya Prakash","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulika","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.4155\/bio.12.83","article-title":"LC-MS\/MS method for simultaneous estimation of candesartan and hydrochlorothiazide in human plasma and its use in clinical pharmacokinetics","volume":"4","author":"Bharathi","year":"2012","journal-title":"Bioanalysis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/VHRM.S49118","article-title":"Safety, tolerability, and efficacy of a fixed dose combination of olmesartan 40 mg and hydrochlorothiazide 12.5\/25 mg in daily practice","volume":"9","author":"Bramlage","year":"2013","journal-title":"Vasc. Health Risk Manag."},{"key":"B3","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.amjhyper.2003.11.003","article-title":"Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide","volume":"17","author":"Chrysant","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"B4","first-page":"178","article-title":"Validated reversed phase High Performance Liquid Chromatography method for simultaneous estimation of olmesartan medoxomil, hydrochlorothiazide and amlodipine besylate in newly designed pharmaceutical dosage forms","volume":"3","author":"Doshi","year":"2012","journal-title":"Int. Res. J. Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jpha.2013.12.003","article-title":"Simultaneous determination of amlodipine, valsartan and hydrochlorothiazide by LC\u2013ESI-MS\/MS and its application to pharmacokinetics in rats","volume":"4","author":"Gadepalli","year":"2014","journal-title":"J. Pharm. Anal."},{"key":"B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jpba.2009.12.012","article-title":"Simultaneous quantitation of hydrochlorothiazide and metoprolol in human plasma by liquid chromatography-tandem mass spectrometry","volume":"52","author":"Gao","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/10601330802600901","article-title":"Pharmacokinetic estimation of Losartan, Losartan carboxylic acid and hydrochlorothiazide in human plasma by LC\/MS\/MS validated method","volume":"25","author":"Goswami","year":"2008","journal-title":"Clin. Res. Regul. Aff."},{"key":"B8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/vhrm.2006.2.4.401","article-title":"Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension","volume":"2","author":"Greathouse","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"article-title":"Guideline for good clinical practice E6(R1)","volume-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use","year":"1996","key":"B9"},{"key":"B10","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/00032710903325906","article-title":"Validated HPLC and HPTLC method for simultaneous quantitation of amlodipine besylate and olmesartan medoxomil in bulk drug and formulation","volume":"43","author":"Kamble","year":"2010","journal-title":"Anal. Lett."},{"key":"B11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/10601333.2013.849267","article-title":"Development and validation of a LC-ESI-MS\/MS method for simultaneous quantification of olmesartan and hydrochlothiazide in human K3EDTA plasma and its application to pharmacokinetic biostudy","volume":"31","author":"Kumar","year":"2014","journal-title":"Clin. Res. Regul. Aff."},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/10826076.2011.597060","article-title":"Challenges in bioanalytical method for simultaneous determination of olmesartan and hydrochlorothiazide in human plasma by liquid chromatography coupled to tandem mass spectrometry","volume":"35","author":"Kumar","year":"2012","journal-title":"J. Liq. Chrom. Rel. Technol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jchromb.2010.01.009","article-title":"Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry","volume":"15","author":"Liu","year":"2010","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"TESH\/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur. Heart J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1255\/ejms.1038","article-title":"High performance liquid chromatography\/negative ion electrospray tandem mass spectrometry method for the measurement of hydrochlorothiazide in human plasma: application to a comparative bioavailability study","volume":"15","author":"Rajasekhar","year":"2009","journal-title":"Eur. J. Mass Spectrom."},{"key":"B17","first-page":"1435","article-title":"Simultaneous quantitation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in pharmaceutical dosage form by using HPLC","volume":"3","author":"Rao","year":"2011","journal-title":"Int. J. Pharmtech. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/0250-474X.62245","article-title":"Spectrophotometric estimation of olmesartan medoxomil and hydrochlorthiazide in tablet","volume":"72","author":"Rote","year":"2010","journal-title":"Indian J. Pharm. Sci."},{"key":"B19","first-page":"536","article-title":"Simultaneous quantitative determination of olmesartan and hydrochlorothiazide in human plasma by Liquid chromatography-tandem mass spectrometry","volume":"6","author":"Sable","year":"2016","journal-title":"Am. J. PharmTech Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1254\/fpj.124.257","article-title":"Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker","volume":"124","author":"Sada","year":"2004","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/bmc.1447","article-title":"Development and validation of an LC-ESI-MS\/MS method for simultaneous quantitation of olmesartan and pioglitazone in rat plasma and its pharmacokinetic application","volume":"24","author":"Sengupta","year":"2010","journal-title":"Biomed. Chromatogr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1365\/s10337-009-0950-1","article-title":"Simultaneous LC\u2013MS\u2013MS analysis of valsartan and hydrochlorothiazide in human plasma","volume":"69","author":"Shah","year":"2009","journal-title":"Chromatographia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.4103\/0250-474X.39447","article-title":"Development and validation of a simultaneous HPTLC method for the estimation of olmesartan medoxomil and hydrochlorothiazide in tablet dosage form","volume":"69","author":"Shah","year":"2007","journal-title":"Indian J. Pharm. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jpba.2009.10.023","article-title":"Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: application to bioequivalence studies","volume":"51","author":"Tutunji","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1016\/j.jchromb.2009.04.021","article-title":"Simultaneous determination of bisoprolol and hydrochlorothiazide in human plasma by HPLC coupled with tandem mass spectrometry","volume":"877","author":"Tutunji","year":"2009","journal-title":"J. Chromatogr. B"},{"key":"B26","unstructured":"Guidance for Industry Bioanalytical Method ValidationRockville, MD2001"},{"key":"B27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1365\/s10337-007-0453-x","article-title":"LC-MS-MS determination of olmesartan in human plasma","volume":"67","author":"Vaidya","year":"2008","journal-title":"Chromatographia"},{"key":"B28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4103\/0250-474X.58190","article-title":"Simultaneous estimation of amlodipine besilate and olmesartan medoxomil in pharmaceutical dosage form","volume":"71","author":"Wankhede","year":"2009","journal-title":"Indian J. Pharm. Sci."},{"key":"B29","first-page":"219","article-title":"Pharmacokinetics of olmesartan, a new angiotensin II receptor blocker, in Chinese healthy subjects","volume":"6","author":"Yu","year":"2006","journal-title":"Asian J. Pharmacodyn. Pharmacokinet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1097\/00004872-200306000-00001","article-title":"European Society of Hypertension-European Society of Cardiology Guidelines for the management of arterial hypertension","volume":"21","author":"Zanchetti","year":"2003","journal-title":"J. Hypertens."},{"key":"B31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40119-017-0087-5","article-title":"Management of hypertension using olmesartan alone or in combination","volume":"6","author":"Zhang","year":"2017","journal-title":"Cardiol. Ther."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00810\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T03:35:46Z","timestamp":1563852946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2019.00810\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":31,"alternative-id":["10.3389\/fphar.2019.00810"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2019.00810","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2019,7,23]]},"article-number":"810"}}